2026-05-23T05:24:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/253802025-12-18T12:59:54Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_19609col_20.500.12105_16967

00925njm 22002777a 4500 dc Pérez-Gimeno, Gloria author Mazagatos, Clara author Lorusso, Nicola author Basile, Luca author Martínez-Pino, Isabel author Corpas-Burgos, Francisca author Batalla Rebolla, Noa author Rumayor-Zarzuelo, Mercedes Belén author Andreu Ivorra, Blanca author Giménez Duran, Jaume author Castrillejo, Daniel author Guiu Cañete, Inés author Huerta Huerta, Marta author García Becerril, Marta author Ramos Marín, Violeta author Casas Flecha, Inmaculada author Pozo Sanchez, Francisco author Monge Corella, Susana author SiVIRA group author 2024-10 During 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case-control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09. Euro Surveill. 2024 Oct;29(40):2400618. 10.2807/1560-7917.ES.2024.29.40.2400618 1560-7917 1025-496X Euro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin 39364601 https://hdl.handle.net/20.500.12105/25380 Children Influenza Test-negative design Vaccine effectiveness Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24